Clinical massively parallel sequencing

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The newest advances in DNA sequencing are based on technologies that perform massively parallel sequencing (MPS). Since 2006, the output from MPS platforms has increased from 20 Mb to >7 Tb. First-generation MPS platforms amplify individual DNA molecules to multiple copies and then interrogate the sequence of those molecules. Second-generation MPS analyzes single unamplified molecules to generate much longer sequence reads but with less output than first-generation MPS and lower first-pass accuracy. With MPS technologies, it is now possible to analyze genomes, exomes, a defined subset of genes, transcriptomes, and even methylation across the genome. These technologies have and will continue to completely transform the clinical practice. CONTENT: The major first- and second-generation MPS platforms and how they are used in clinical practice are discussed. SUMMARY: The ability to sequence terabases of DNA per run on an MPS platform will dramatically change how DNA sequencing is used in clinical practice. Currently, MPS of targeted gene panels is the most common use of this technology clinically, but as the cost for genome sequencing inches downward to $100, this may soon become the method of choice (with the caveat that, at least in the near term, clinical-grade genome sequencing with interpretation may cost much more than $100). Other uses of this technology include sequencing of a mixture of bacterial and viral species (metagenomics), as well as the characterization of methylation across the genome.

Original languageEnglish (US)
Pages (from-to)77-88
Number of pages12
JournalClinical chemistry
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

High-Throughput Nucleotide Sequencing
Genes
Genome
Technology
Methylation
DNA
Molecules
DNA Sequence Analysis
Exome
Costs and Cost Analysis
Metagenomics
Costs
Transcriptome

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Clinical massively parallel sequencing. / Gao, Ge; Smith, David I.

In: Clinical chemistry, Vol. 66, No. 1, 01.01.2020, p. 77-88.

Research output: Contribution to journalArticle

Gao, Ge ; Smith, David I. / Clinical massively parallel sequencing. In: Clinical chemistry. 2020 ; Vol. 66, No. 1. pp. 77-88.
@article{fcc1263b10b64bc8a3a42aa29f1b9744,
title = "Clinical massively parallel sequencing",
abstract = "BACKGROUND: The newest advances in DNA sequencing are based on technologies that perform massively parallel sequencing (MPS). Since 2006, the output from MPS platforms has increased from 20 Mb to >7 Tb. First-generation MPS platforms amplify individual DNA molecules to multiple copies and then interrogate the sequence of those molecules. Second-generation MPS analyzes single unamplified molecules to generate much longer sequence reads but with less output than first-generation MPS and lower first-pass accuracy. With MPS technologies, it is now possible to analyze genomes, exomes, a defined subset of genes, transcriptomes, and even methylation across the genome. These technologies have and will continue to completely transform the clinical practice. CONTENT: The major first- and second-generation MPS platforms and how they are used in clinical practice are discussed. SUMMARY: The ability to sequence terabases of DNA per run on an MPS platform will dramatically change how DNA sequencing is used in clinical practice. Currently, MPS of targeted gene panels is the most common use of this technology clinically, but as the cost for genome sequencing inches downward to $100, this may soon become the method of choice (with the caveat that, at least in the near term, clinical-grade genome sequencing with interpretation may cost much more than $100). Other uses of this technology include sequencing of a mixture of bacterial and viral species (metagenomics), as well as the characterization of methylation across the genome.",
author = "Ge Gao and Smith, {David I.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1373/clinchem.2019.303305",
language = "English (US)",
volume = "66",
pages = "77--88",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical massively parallel sequencing

AU - Gao, Ge

AU - Smith, David I.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - BACKGROUND: The newest advances in DNA sequencing are based on technologies that perform massively parallel sequencing (MPS). Since 2006, the output from MPS platforms has increased from 20 Mb to >7 Tb. First-generation MPS platforms amplify individual DNA molecules to multiple copies and then interrogate the sequence of those molecules. Second-generation MPS analyzes single unamplified molecules to generate much longer sequence reads but with less output than first-generation MPS and lower first-pass accuracy. With MPS technologies, it is now possible to analyze genomes, exomes, a defined subset of genes, transcriptomes, and even methylation across the genome. These technologies have and will continue to completely transform the clinical practice. CONTENT: The major first- and second-generation MPS platforms and how they are used in clinical practice are discussed. SUMMARY: The ability to sequence terabases of DNA per run on an MPS platform will dramatically change how DNA sequencing is used in clinical practice. Currently, MPS of targeted gene panels is the most common use of this technology clinically, but as the cost for genome sequencing inches downward to $100, this may soon become the method of choice (with the caveat that, at least in the near term, clinical-grade genome sequencing with interpretation may cost much more than $100). Other uses of this technology include sequencing of a mixture of bacterial and viral species (metagenomics), as well as the characterization of methylation across the genome.

AB - BACKGROUND: The newest advances in DNA sequencing are based on technologies that perform massively parallel sequencing (MPS). Since 2006, the output from MPS platforms has increased from 20 Mb to >7 Tb. First-generation MPS platforms amplify individual DNA molecules to multiple copies and then interrogate the sequence of those molecules. Second-generation MPS analyzes single unamplified molecules to generate much longer sequence reads but with less output than first-generation MPS and lower first-pass accuracy. With MPS technologies, it is now possible to analyze genomes, exomes, a defined subset of genes, transcriptomes, and even methylation across the genome. These technologies have and will continue to completely transform the clinical practice. CONTENT: The major first- and second-generation MPS platforms and how they are used in clinical practice are discussed. SUMMARY: The ability to sequence terabases of DNA per run on an MPS platform will dramatically change how DNA sequencing is used in clinical practice. Currently, MPS of targeted gene panels is the most common use of this technology clinically, but as the cost for genome sequencing inches downward to $100, this may soon become the method of choice (with the caveat that, at least in the near term, clinical-grade genome sequencing with interpretation may cost much more than $100). Other uses of this technology include sequencing of a mixture of bacterial and viral species (metagenomics), as well as the characterization of methylation across the genome.

UR - http://www.scopus.com/inward/record.url?scp=85077655107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077655107&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2019.303305

DO - 10.1373/clinchem.2019.303305

M3 - Article

C2 - 31811004

AN - SCOPUS:85077655107

VL - 66

SP - 77

EP - 88

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -